

# References

## Acidosis

*\*CKM Acidosis Guideline adapted from the AHS Acidosis (Metabolic) Management Guideline (June 2015), Alberta Kidney Care (AKC), Chronic Kidney Disease Clinics.*

---

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International*, 3, 1-150.

Kovesdy, C. Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease. Kovesdy, Csaba. In: Post T, ed. *UptoDate*. Waltham, MA: UptoDate; 2016. [www.uptodate.com](http://www.uptodate.com). Accessed June 22, 2016.

National Kidney Foundation Kidney Disease Outcomes Quality Initiative: K/DOQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. (2003). *American Journal of Kidney Disease*. 3(42), 70-77. Available from: [http://www.kidney.org/professionals/KDOQI/guidelines\\_bone/Guide1.htm](http://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm)

## Anemia

*\*CKM Anemia Guideline adapted from the AHS Anemia Management Guideline (May 2015), Alberta Kidney Care (AKC) - CKD, PD, HD Programs.*

---

Gandra SR, Finkelstein FO, Bennett A V., Lewis EF, Brazg T, Martin ML. Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review. *Am J Kidney Dis*. 2010;55(3):519-534. doi:10.1053/j.ajkd.2009.09.019.

Roger SD, Jassal S V., Woodward MC, Soroka S, McMahon LP. A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. *Int Urol Nephrol*. 2014;46(2):469-475. doi:10.1007/s11255-013-0512-1.

## Blood Pressure

---

Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. *Jama*. 2015;314(2):170. doi:10.1001/jama.2015.7517.

Dalhousie University Academic Detailing Service and the Palliative and Therapeutic Harmonization (PATH) Program. Treating Hypertension In Frailty. Path Clinic. [http://pathclinic.ca/wp-content/uploads/2013/12/Treating-Hypertension\\_PATH-Nov-2013.pdf](http://pathclinic.ca/wp-content/uploads/2013/12/Treating-Hypertension_PATH-Nov-2013.pdf). Accessed June 22, 2016.

Muller M, Smulders YM, de Leeuw PW, Stehouwer CD a. Treatment of Hypertension in the Oldest Old: A Critical Role for Frailty? *Hypertension*. 2014;63(3):433-441. doi:10.1161/HYPERTENSIONAHA.113.00911.

## Breathlessness and EOL Breathlessness

---

Booth S, Moffat C, Burkin J, Galbraith S, Bausewein C. Nonpharmacological interventions for breathlessness. *Curr Opin Support Palliat Care*. 2011;5(2):77-86. doi:10.1097/SPC.0b013e3283460c93.

Brown, E., Murtagh, F. & Murphy, E. Management of the last few days. In *Kidney disease from advanced disease to bereavement*. 2<sup>nd</sup> ed. Oxford, UK: Oxford University Press. 2012: 253-295.

Cheng H, Sham M, Chan K, Li C, Au H, Yip T. Combination therapy with low-dose metolazone and furosemide: a “needleless” approach in managing refractory fluid overload in elderly renal failure patients under palliative care. *Int Urol Nephrol*. 2014;46(9):1809-1813. doi:10.1007/s11255-014-0724-z.

Douglas C, Murtagh F, Chambers E, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. *Palliat Med*. 2009;23(2):103-110. doi:10.1177/0269216308100247.

Fraser Health Hospice Palliative Care Clinical Practice Committee. Hospice Palliative Care Program Symptom Guidelines: Dyspnea. Fraser Health. <https://www.fraserhealth.ca/media/Dyspnea.pdf>. Published July 17, 2006. Accessed June 22, 2016.

Liverpool Care Pathway for the Dying Patient: Pathway for Renal Patients Version 2. Date of Issue May 2011.

Murtagh, F., & Weisbord, S.D. Symptoms in renal disease; their epidemiology, assessment, and management. In E.J. Chambers, E.A. Brown & M.J. Germain, ed. *Supportive care for the renal patient*. 2<sup>nd</sup> Ed. New York: Oxford University Press Inc. 2010: 103-132.

National LCP Steering Group. Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Failure, Estimated Glomerular Filtration Rate <30 ml/min. Liverpool Care Pathway for the Dying Patient (LCP).

[http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s\\_LCP\\_Medical\\_Guidance\\_for\\_Patients\\_with\\_Renal\\_Failure\\_2008.pdf](http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s_LCP_Medical_Guidance_for_Patients_with_Renal_Failure_2008.pdf)

Published 2008. Accessed June 22, 2016.

Pereira, JL, ed. The Pallium palliative pocketbook: a peer-reviewed, referenced resource. Edmonton, Canada: The Pallium Project; 2008.

Renal and Hypertension Service, St. George and Sutherland Hospitals. End of Life Symptom Control in ESKD: Flowcharts.

[http://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/End%20of%20Life%20symptom%20flowcharts\\_2015.pdf](http://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/End%20of%20Life%20symptom%20flowcharts_2015.pdf). Published 2015. Accessed June 22, 2016.

Renal and Hypertension Service, St. George and Sutherland Hospitals. Palliative Care Drugs in Renal Failure.

[https://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/Pallcare%20pain%20medsv6\\_17%208%202015.pdf](https://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/Pallcare%20pain%20medsv6_17%208%202015.pdf). Published 2015. Accessed June 22, 2016.

Richard Bright Services. Guidelines on Supportive Care, Symptom Control and End of Life Care for Renal Patients with Chronic Kidney Disease (CKD): Information for Health Care Professionals. The Richard Bright Renal Services, North Bristol NHS Trust: October 2014.

Russon, L., Hicks, F. Yorkshire & the Humber Conservative Kidney Management Strategy. March 2012.

## Calcium and Phosphorus

*\*CKM Calcium and Phosphorus Guideline adapted from the AHS Mineral Bone Management Guideline (June 2015), Alberta Kidney Care (AKC), Chronic Kidney Disease Clinics.*

---

## Dyslipidemia

AHS Dyslipidemia Management Clinical Algorithm (January 2015), Alberta Kidney Care (AKC) – Chronic Kidney Disease (CKD) Clinics.

---

Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. *Jama*. 2015;314(2):170. doi:10.1001/jama.2015.7517.

Dalhousie University Academic Detailing Service and the Palliative and Therapeutic Harmonization (PATH) Program. Treating Hyperlipidemia in Severe and Very Severe Frailty. Path Clinic. [http://pathclinic.ca/wp-content/uploads/2013/11/Treating-Hyperlipidemia\\_PATH-Nov-2013.pdf](http://pathclinic.ca/wp-content/uploads/2013/11/Treating-Hyperlipidemia_PATH-Nov-2013.pdf). Accessed June 22, 2016.

Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness. *JAMA Intern Med*. 2015;175(5):691. doi:10.1001/jamainternmed.2015.0289.

Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. *J Palliat Med*. 2008;11(5):685-693. doi:10.1089/jpm.2007.0215.

Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and Treatment of Older Patients With Hypercholesterolemia. *Jama*. 2014;312(11):1136. doi:10.1001/jama.2014.10924.

## Fatigue/Sleep Difficulties

---

Alam A, Voronovich Z, Carley JA. A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions. *The Primary Care Companion for CNS Disorders*. 2013;15(5):PCC.13r01525.

BC Renal Agency. Symptom management resources-insomnia. BC Provincial Health Services Authority. <http://www.bcrenalagency.ca/resource-gallery/Documents/SymptomManagementProtocolInsomnia1.pdf>. Updated November 2012. Accessed June 22, 2016.

Canadian Agency for Drugs and Technologies in Health. Treatment of Older Adults with Insomnia, Agitation, or Delirium with Benzodiazepines: A Review of the Clinical Effectiveness and Guidelines. January 14, 2016.

Cheuk D, Yeung W, Chung K, Wong V. Acupuncture for insomnia (Review). *Cochrane Database Syst Rev*. 2012;(9).

Clair AG. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. *Sleep Med Rev.* 2014;18(3):261-271. doi:10.1016/j.smrv.2013.07.005.

Furey SA, Hull SG, Leibowitz MT, Jayawardena S, Roth T. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. *J Clin Sleep Med.* 2014;10(10):1101-1109. doi:10.5664/jcsm.4110.

Garcia Borreguero D, Patrick J, Dubrava S, et al. Pregabalin Versus Pramipexole: Effects on Sleep Disturbance in Restless Legs Syndrome. *Sleep.* 2014;37(4):635-643. doi: 10.5665/sleep.3558.

Jhamb M, Liang K, Yabes J, et al. Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: Are sleep disorders a key to understanding fatigue? *Am J Nephrol.* 2013;38(6):489-495. doi:10.1159/000356939.

Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T. Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. *Sleep Med.* 2012;13(2):133-138. doi:10.1016/j.sleep.2011.09.006.

Lo H-S, Yang C-M, Lo HG, Lee C-Y, Ting H, Tzang B-S. Treatment effects of gabapentin for primary insomnia. *Clin Neuropharmacol.* 2010;33(2):84-90. doi:10.1097/WNF.0b013e3181cda242.

McMillan, J., Aitken, E., Holroyd-Leduc J. Management of insomnia and long-term use of sedative-hypnotic drugs in older patients. *CMAJ.* 2013;185(17):1499-1505. doi:10.1503/cmaj.130260.

Murtagh FEM, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. *EDTNA ERCA J.* 2006;32(2):93-98.

Rosenberg, R., Hull, S., Lankford A. A randomized, double-blind, single-dose, placebo-controlled, multicenter polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. *J Clin Sleep Med.* 2014;10(10):1093-1100. doi:10.5664/jcsm.4110.

Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "it feels like my body is just worn out". *JAMA.* 2007;297(3):295-304. doi:10.1001/jama.298.2.217.

## Hyperkalemia

\*CKM Hyperkalemia Guideline adapted from the AHS CKD Pathway Management of Elevated Serum Potassium. [http://www.ckdpathway.ca/Content/pdfs/Management\\_of\\_elevated\\_serum\\_potassium.pdf](http://www.ckdpathway.ca/Content/pdfs/Management_of_elevated_serum_potassium.pdf). Accessed June 22, 2016.

---

## Nausea and Vomiting and EOL Nausea and Vomiting

---

Brown MA, Crail SM. ANZSN Renal Supportive Care Guidelines 2013. *Nephrology*. 2013;18:401-454.

Douglas C, Murtagh F, Chambers E, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. *Palliat Med*. 2009;23(2):103-110. doi:10.1177/0269216308100247.

Liverpool Care Pathway for the Dying Patient: Pathway for Renal Patients Version 2. Date of Issue May 2011.

National LCP Steering Group. Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Failure, Estimated Glomerular Filtration Rate <30 ml/min. Liverpool Care Pathway for the Dying Patient (LCP).

[http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s\\_LCP\\_Medical\\_Guidance\\_for\\_Patients\\_with\\_Renal\\_Failure\\_2008.pdf](http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s_LCP_Medical_Guidance_for_Patients_with_Renal_Failure_2008.pdf)

Published 2008. Accessed June 22, 2016.

O'Connor N, Corcoran A. End-Stage Renal Disease: Symptom Management and Advance Care Planning. 2012;85(7).

Pereira, JL, ed. The Pallium palliative pocketbook: a peer-reviewed, referenced resource. Edmonton, Canada: The Pallium Project; 2008.

Renal and Hypertension Service, St. George and Sutherland Hospitals. End of Life Symptom Control in ESKD: Flowcharts.

[http://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/End%20of%20Life%20symptom%20flowcharts\\_2015.pdf](http://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/End%20of%20Life%20symptom%20flowcharts_2015.pdf). Published 2015. Accessed June 22, 2016.

Renal and Hypertension Service, St. George and Sutherland Hospitals. Palliative Care Drugs in Renal Failure.

[https://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/Pallcare%20pain%20medsv6\\_17%208%202015.pdf](https://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/Pallcare%20pain%20medsv6_17%208%202015.pdf). Published 2015. Accessed June 22, 2016.

Richard Bright Services. Guidelines on Supportive Care, Symptom Control and End of Life Care for Renal Patients with Chronic Kidney Disease (CKD): Information for Health Care Professionals. The Richard Bright Renal Services, North Bristol NHS Trust: October 2014.

## Pain: Nociceptive and Neuropathic and EOL Pain

---

BC Renal Agency. Renal Analgesic Brochure. BC Provincial Health Services Authority.  
<http://www.bcrenalagency.ca/resource-gallery/Documents/Renal-Analgesic-Brochure.pdf>. Published October 2011. Accessed June 22, 2016.

Brown E, Murtagh F, Murphy, E. The management of pain. In *Kidney disease from advanced disease to bereavement*. 2<sup>nd</sup> ed. Oxford, UK: Oxford University Press. 2012:103-136.

Brown, E., Murtagh, F. Murphy, E. Management of the last few days. In *Kidney disease from advanced disease to bereavement*. 2<sup>nd</sup> ed. Oxford, UK: Oxford University Press. 2012: 253-295.

Davison S, Ferro C. Management of pain in chronic kidney disease. *Progress in Palliative Care*. 2009;17(4):186-195. doi:10.1179/096992609x12455871937189.

Davison S, Chambers EJ, Ferro, CJ. Management of pain in renal failure. In E.J. Chambers, E.A. Brown & M.J. Germain, ed. *Supportive care for the renal patient*. 2<sup>nd</sup> Ed. New York: Oxford University Press Inc. 2010: 139-188.

Davison S, Koncicki H, Brennan F. Pain in Chronic Kidney Disease: A Scoping Review. *Semin Dial*. 2014;27(2):188-204. doi:10.1111/sdi.12196.

Davison, S, Curhan GC, Sheridan AM. Management of chronic pain in chronic kidney disease. In: Post T, ed. *UptoDate*. Waltham, MA: UptoDate, 2015. [www.uptodate.com](http://www.uptodate.com). Accessed October 09, 2015.

Johnson, SJ, Kral, LA, Hegeman, R, Mueller, BA. Opioid safety in patients with renal or hepatic dysfunction. *Pain Treatment Topics*. <http://paincommunity.org/blog/wp-content/uploads/Opioids-Renal-Hepatic-Dysfunction.pdf>. Published November 30, 2007. Accessed June 22, 2016.

Murtagh F, Addington-Hall J, Donohoe P, Higginson I. Symptom management in patients with established renal failure managed without dialysis. *EDTNA-ERCA Journal*. 2006;32(2):93-98. doi:10.1111/j.1755-6686.2006.tb00459.x.

Murtagh F, Chai M, Donohoe P, Edmonds P, Higginson I. The Use of Opioid Analgesia in End-Stage Renal Disease Patients Managed Without Dialysis. *Journal of Pain & Palliative Care Pharmacotherapy*. 2007;21(2):5-16. doi:10.1080/j354v21n02\_03.

Northern and Southern Alberta Renal Program (NARP & SARP). Pain algorithms & preferred analgesics for chronic pain in patients with chronic kidney disease Stages 4 and 5. July 2010.

## Pruritus

---

BC Renal Agency. Symptom management resources-pruritus. BC Provincial Health Services Authority. <http://www.bcrenalagency.ca/resource-gallery/Documents/SymptomManagementProtocolPruritus1.pdf>. Updated November 2012. Accessed June 22, 2016.

Cheikh Hassan HI, Brennan F, Collett G, Josland E a., Brown M a. Efficacy and Safety of Gabapentin for Uremic Pruritus and Restless Legs Syndrome in Conservatively Managed Patients With Chronic Kidney Disease. *J Pain Symptom Manage*. 2015;49(4):782-789. doi:10.1016/j.jpainsymman.2014.08.010.

Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. *Nephrol Dial Transplant*. 2004;19(12):3137-3139. doi:10.1093/ndt/gfh496.

Ki D. Pruritus in Uremia: Protocol. *The Joanna Briggs Institute*. 2013.

Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyani S, Mohseni M. Gabapentin: a promising drug for the treatment of uremic pruritus. *Saudi J Kidney Dis Transplant*. 2007;18(3):378-381.

Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, Nasli Esfahani E, Farrokhi F. Low-dose doxepin for treatment of pruritus in patients on hemodialysis. *Iran J Kidney Dis*. 2007;1(1):34-37.

Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study. *Nephrology*. 2012;17(8):710-717. doi:10.1111/j.1440-1797.2012.01655.x.

Xander C, Meerpohl JJ, Galandi D, et al. Pharmacological interventions for pruritus in adult palliative care patients. *Cochrane database Syst Rev*. 2013;6(6):CD008320. doi:10.1002/14651858.CD008320.pub2.

Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. *J Dermatolog Treat*. 2009;20(2):76-81. doi:10.1080/09546630802441218.



## Restless Legs Syndrome

---

Cheikh Hassan HI, Brennan F, Collett G, Josland E a., Brown M a. Efficacy and Safety of Gabapentin for Uremic Pruritus and Restless Legs Syndrome in Conservatively Managed Patients With Chronic Kidney Disease. *J Pain Symptom Manage*. 2015;49(4):782-789. doi:10.1016/j.jpainsymman.2014.08.010

Comella CL. Treatment of Restless Legs Syndrome. *Neurotherapeutics*. 2014;11(1):177-187. doi:10.1007/s13311-013-0247-9.

de Oliveira MM, Conti CF, Valbuza JS, de Carvalho LBC, do Prado GF. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. *Mov Disord*. 2010;25(10):1335-1342. doi:10.1002/mds.22955.

Giannaki CD, Sakkas GK, Karatzaferi C, et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. *BMC Nephrol*. 2013;14(1):194. doi:10.1186/1471-2369-14-194.

Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, Pantzaris MC, Stefanidis I, Sakkas GK. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. *Kidney Int*. 2013;85:1275-1282. doi:10.1038/ki.2013.394.

Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M. Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. *Ren Fail*. 2004;26(4):393-397. doi:10.1081/JDI-120039823.

Miranda, M., Kagi, M., Fabres, L., Aguilera, MD; M. Alvo, MD; L. Elgueta, MD; S. Erazo, MD; and P. Venegas M. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. *Neurology*. 2004;March(1):831-832.

Molnar MZ, Novak M, Mucsi I. Management of restless legs syndrome in patients on dialysis. *Drugs*. 2006;66(5):607-624. doi:http://dx.doi.org/10.2165/00003495-200666050-00003.

Sakkas GK, Giannaki CD, Karatzaferi C, et al. Current trends in the management of uremic restless legs syndrome: A systematic review on aspects related to quality of life, cardiovascular mortality and survival. *Sleep Med Rev*. 2015;21:39-49.

Thorp, M., Morris, C., Bagby S. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. *Am J Kidney Dis*. 2001;38(1):104-108.

## Restlessness

---

Fraser Health Hospice Palliative Care Clinical Practice Committee. Hospice Palliative Care Program Symptom Guidelines: Delirium/Restlessness. Fraser Health.  
<https://www.fraserhealth.ca/media/07FHSymptomGuidelinesDelirium.pdf>. Published November 24, 2006. Accessed June 22, 2016.

Liverpool Care Pathway for the Dying Patient: Pathway for Renal Patients Version 2. Date of Issue May 2011.

National LCP Steering Group. Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Failure, Estimated Glomerular Filtration Rate <30 ml/min. Liverpool Care Pathway for the Dying Patient (LCP).  
[http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s\\_LCP\\_Medical\\_Guidance\\_for\\_Patients\\_with\\_Renal\\_Failure\\_2008.pdf](http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s_LCP_Medical_Guidance_for_Patients_with_Renal_Failure_2008.pdf)  
Published 2008. Accessed June 22, 2016.

Pereira, JL, ed. The Pallium palliative pocketbook: a peer-reviewed, referenced resource. Edmonton, Canada: The Pallium Project; 2008.

Renal and Hypertension Service, St. George and Sutherland Hospitals. End of Life Symptom Control in ESKD: Flowcharts.  
[http://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/End%20of%20Life%20symptom%20flowcharts\\_2015.pdf](http://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/End%20of%20Life%20symptom%20flowcharts_2015.pdf). Published 2015. Accessed June 22, 2016.

Renal and Hypertension Service, St. George and Sutherland Hospitals. Palliative Care Drugs in Renal Failure.  
[https://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/Pallcare%20pain%20medsv6\\_17%208%202015.pdf](https://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/Pallcare%20pain%20medsv6_17%208%202015.pdf). Published 2015. Accessed June 22, 2016.

Richard Bright Services. Guidelines on Supportive Care, Symptom Control and End of Life Care for Renal Patients with Chronic Kidney Disease (CKD): Information for Health Care Professionals. The Richard Bright Renal Services, North Bristol NHS Trust: October 2014.

Russon, L., Hicks, F. Yorkshire & the Humber Conservative Kidney Management Strategy. March 2012.

## Respiratory Tract Secretions in the last weeks to days of life

---

Fraser Health Hospice Palliative Care Clinical Practice Committee. Hospice Palliative Care Program Symptom Guidelines: Terminal Secretions/Congestion. Fraser Health.

<https://www.fraserhealth.ca/media/18FHSymptomGuidelinesTerminalSecretions.pdf> Published November 24, 2006. Accessed June 22, 2016.

Liverpool Care Pathway for the Dying Patient: Pathway for Renal Patients Version 2. Date of Issue May 2011.

National LCP Steering Group. Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Failure, Estimated Glomerular Filtration Rate <30 ml/min. Liverpool Care Pathway for the Dying Patient (LCP).

[http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s\\_LCP\\_Medical\\_Guidance\\_for\\_Patients\\_with\\_Renal\\_Failure\\_2008.pdf](http://www.trinityhospice.co.uk/wp-content/uploads/2011/08/s_LCP_Medical_Guidance_for_Patients_with_Renal_Failure_2008.pdf) Published 2008. Accessed June 22, 2016.

Pereira, JL, ed. The Pallium palliative pocketbook: a peer-reviewed, referenced resource. Edmonton, Canada: The Pallium Project; 2008.

Renal and Hypertension Service, St. George and Sutherland Hospitals. End of Life Symptom Control in ESKD: Flowcharts.

[http://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/End%20of%20Life%20symptom%20flowcharts\\_2015.pdf](http://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/End%20of%20Life%20symptom%20flowcharts_2015.pdf). Published 2015. Accessed June 22, 2016.

Renal and Hypertension Service, St. George and Sutherland Hospitals. Palliative Care Drugs in Renal Failure.

[https://stgrenal.org.au/sites/default/files/upload/Renal\\_supportive\\_care/Pallcare%20pain%20medsv617%208%202015.pdf](https://stgrenal.org.au/sites/default/files/upload/Renal_supportive_care/Pallcare%20pain%20medsv617%208%202015.pdf). Published 2015. Accessed June 22, 2016.

Richard Bright Services. Guidelines on Supportive Care, Symptom Control and End of Life Care for Renal Patients with Chronic Kidney Disease (CKD): Information for Health Care Professionals. The Richard Bright Renal Services, North Bristol NHS Trust: October 2014.

Russon, L., Hicks, F. Yorkshire & the Humber Conservative Kidney Management Strategy. March 2012.